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Significance Statement 
Most patients with depression do not respond to the first treatment they try and in many cases 
multiple attempts are necessary to relieve symptoms. The fact that depression affects about 
20% of the population at least once in their lifetime means that this problem applies to a 
substantial number of individuals. The delay in finding effective treatment, often extending to 
months or years, translates into unnecessary personal suffering and burden. This burden could 
be lessened if there were tests indicating those patients who are unlikely to respond to first 
line treatment and require higher intensity treatment from outset. This study, using functional 
imaging, has added to the growing body of evidence pointing at the pregenual anterior 
cingulate cortex as a reliable predictor of subsequent treatment response in depression. Such 
studies bring us closer to the application of biological markers to predict therapeutic response 
in clinical practice.  
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Abstract  
Background: Identification of biomarkers predicting therapeutic outcome to antidepressant 
treatment is one of the most important tasks in current research because it may transform the 
lengthy process of finding the right treatment for a given individual with depression. In the 
current study we explored the potential of pre-treatment pregenual anterior cingulate cortex 
(pgACC) activity as a putative biomarker of treatment response.  
Methods: Thirty-two medication-free patients with depression were treated for 6 weeks with 
a selective serotonin reuptake inhibitor, escitalopram. Before treatment began, patients 
underwent an fMRI scan testing response to brief, masked, presentations of facial expression 
depicting sadness and happiness.  
Results: After 6 weeks of treatment there were 20 SSRI responders and 12 non-responders. 
Increased pre-treatment pgACC activity to sad versus happy faces was observed in 
responders relative to non-responders. A leave one out analysis suggested that activity in the 
ACC was able to predict response status at the level of the individual participant..  
Conclusions: The study supports the notion of pgACC as a promising predictor of 
antidepressant response.    
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Introduction 
The search for biomarkers that can predict clinical response to the pharmacotherapy of 
depression is a task of substantial practical importance.  Only 50% of patients respond to the 
first treatment they try, and remission rates are even lower (around 30%) (Rush et al. 2009). 
Many patients will take 2 or more different antidepressants before finding a drug that works 
for them (Warden et al. 2007). Identifying patients unlikely to respond to first line treatment 
may speed up the application of second line or adjunct treatments and improve overall time to 
remission.   
Studies employing neuroimaging have led to the identification of a number of candidates for 
treatment response prediction biomarkers (eg. McGarth et al. 2013, Dunlop et al. 2017). One 
of the best established is increased pre-treatment activity in the pregenual anterior cingulate 
cortex (pgACC) which has been linked to a positive therapeutic response to antidepressant 
treatments. In a review of 23 imaging studies, Pizzagalli (2011) concluded that increased 
activity in the rostral ACC (rACC; equivalent to pgACC) both in the resting state, and in 
response to simple cognitive tasks, was associated with positive outcome to a variety of 
treatment modalities including pharmacotherapy, transcranial magnetic stimulation and sleep 
deprivation. This was also shown in a meta-analysis by Fu et al. (2013). 
Of the studies reviewed by Pizzagalli (2011) and Fu (2013), five and fourteen, respectively, 
employed fMRI, the most widely available modality for imaging the ACC in depressed 
patients. Since these publications, a number of further fMRI studies have been conducted, 
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including a study by our group in which we reported that neural changes in response to an 
emotional processing task after one week of treatment with the selective serotonin re-uptake 
inhibitor (SSRI), escitalopram, predicted clinical outcome after six weeks of treatment in a 
group of 32 depressed patients (Godlewska et al. 2016). The present report concerns baseline 
(pre-treatment) neural responses of this patient group to a different emotional task that 
employed masked faces as ‘implicit’ (non-conscious) stimuli and their potential to act as 
predictors of subsequent response to escitalopram.  
Interestingly a similar implicit task was employed in a recent fMRI investigation, which also 
found a correlation between pre-treatment activity in pgACC during the emotional processing 
task and the subsequent response to eight weeks of treatment with the selective serotonin re-
uptake inhibitor (SSRI), sertraline, in ten unmedicated patients (Victor et al. 2013). This 
study was designed to assess whether the results can be replicated in a larger group, allowing 
for a categorical classification of patients into responders and non-responders. A similar task 
was used, based on the concept that structures involved in rapid, non-conscious stimulus 
processing may be particularly reactive to masked stimuli and sensitive to depression (Victor 
et al. 2010, 2013, 2017). 
The aim of the present study was to test this hypothesis that increased  pgACC to masked sad 
facial expressions at baseline would predict later treatment response  and provide an initial 
estimate of the degree to which this effect was able to predict treatment response at the level 
of the individual patient, using a leave-one-out validation process.     
 
 
 
Downloaded from https://academic.oup.com/ijnp/advance-article-abstract/doi/10.1093/ijnp/pyy069/5074739
by Roehampton Institute user
on 22 August 2018
Ac
ce
pte
d M
an
us
cri
pt
 
7 
 
Participants  
Thirty nine patients with major depression consented to take part in the study. Thirty two 
(18F:14M) completed the fMRI scan and the six week period of escitalopram treatment (see 
Table 1 for demographic information). In the remaining seven patients relevant data were not 
available at the end of the treatment period (four patients dropped out before the six week 
assessment, and scanning data from a further three patients were not available due to 
technical issues). All participants were assessed with the Structured Clinical Interview for 
DSM-IV (Spitzer et al. 1995) for the presence of current and past psychiatric disorders. The 
depressed patients met criteria for a primary diagnosis of major depressive disorder; 
exclusion criteria were psychosis or substance dependence as defined by DSM-IV, a 
clinically significant risk of suicidal behaviour, contraindications to escitalopram treatment or 
treatment with psychotropic medication less than three weeks before the study (five weeks 
for fluoxetine), major somatic or neurological disorders, pregnancy or breast-feeding, any 
contra-indications to MR imaging or concurrent medication which could alter emotional 
processing. All participants were right-handed. 
 
The study was approved by the Oxford 
Research Ethics Committee and all participants gave written informed consent.  
 
Study design and drug treatment 
Following the baseline fMRI scan patients received 10mg escitalopram each morning for a 
period of 6 weeks without dose adjustment. Assessment of depressive severity and treatment 
response was made using the 17 items Hamilton Depression Rating Scale (HAM-D) 
(Hamilton 1960), with anxiety being measured with Spielberger’s State-Trait Anxiety 
inventory (STAI) (Spielberger 1989)
 
at baseline and week 6. The fMRI assessments were 
completed at the same time points. The current analysis focuses on how baseline differences 
in the function of pgACC were able to predict clinical response at week six of treatment. 
Methods 
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After the 6 week duration of the study, all patients were offered treatment openly with 
escitalopram according to usual clinical practice. Clinical response to the SSRI was defined 
as a reduction in HAM-D of 50% or more from baseline after six weeks of treatment (Angst 
et al. 1993).
 
  
fMRI data acquisition 
Functional MRI data were acquired on a 3T Siemens TIM TRIO (Siemens AG).   Data were 
acquired with a voxel resolution of 3x3x3mm, TR/TE/FA =2000ms/28ms/89
o
.   A total of 
256 volumes were acquired in an experiment lasting 6 minutes. T1-weighted structural 
images were acquired using a magnetisation prepared rapid acquisition by gradient echo 
(MP-RAGE) sequence with a voxel resolution  1.0x1.0x1.0 mm on a 208 x 256 x 200 grid, 
TE/TI/TR= 4.68/900/2040ms. To monitor cardiac and respiratory processes subjects wore a 
pulse oximeter and respiratory bellows. 
fMRI experimental task 
During fMRI scanning, participants completed a backward masking task. This task consisted 
of viewing pairs of faces, paired in such a way that the first face, expressing sad, happy or 
neutral emotion, was shown for 30ms, and then immediately ‘masked’ by another face of 
neutral expression, shown for 70ms; this procedure has been shown to interfere with explicit 
perception of the first face (Victor et al. 2010). After each pair of faces was presented for 
100ms in total, participants were asked to report the gender of the face via an MRI 
compatible key pad; the gender of both faces was the same. Each participant was shown 4 sad 
blocks, 4 happy blocks and 9 neutral blocks, which were interleaved with sad and happy 
blocks (N-S-N-H-N-S-N-H-N or N-H-N-S-N-H-N-S-N). Between each block, there was a 
10-s block of a baseline fixation cross.  
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fMRI preprocessing and statistical analysis 
Functional MRI data were preprocessed and analysed using FSL (Jenkinson et al. 2012). 
Briefly, motion correction was applied using a rigid body registration to the central volume; 
brain matter was segmented from non-brain using a mesh deformation approach.
. 
Gaussian 
spatial smoothing was applied with a full width half maximum of 5mm; high pass temporal 
filtering was applied using a Gaussian-weighted running lines filter, with a 3dB cut-off of 
120s.
 
A general linear model was fitted in pre-whitened data space. Three explanatory variables 
(plus their temporal derivatives) were modelled: ‘sad faces’, ‘happy faces’ and ‘neutral 
faces’. All explanatory variables were convolved with a default haemodynamic response 
function (Gamma function, delay=6s, standard deviation =3s), and filtered by the same high 
pass filter as the data. The impact of physiological noise on the BOLD signal was reduced 
using the Physiological Noise Modelling (PNM) tool of FSL. Pulse oximetry and respiratory 
bellows data were processed by PNM to create 33 nuisance regressors which were added to 
the first level fMRI model.  The full model was simultaneously regressed against the BOLD 
data, giving the best-fitting amplitudes for each explanatory variable while accounting for the 
physiological noise. 
The task contrast of interest in this study was the relative activation of sad vs. happy faces. 
The degree to which the change in neural activity in this contrast predicted participants’ 
clinical response on the HAM-D to medication over six weeks, was tested using a two level 
analysis. The first level consisted of the sad vs. happy contrast maps, as described above, 
calculated for each depressed subject. Second level, between subject, random effects analysis 
assessed whether this change in neural activity differed between depressed patients who went 
on to respond to the medication and those who did not.  Baseline HAM-D score was included 
Downloaded from https://academic.oup.com/ijnp/advance-article-abstract/doi/10.1093/ijnp/pyy069/5074739
by Roehampton Institute user
on 22 August 2018
Ac
ce
pte
d M
an
us
cri
pt
 
10 
 
as a regressor in the second level analysis to account for the potential influence of initial 
depression severity effects on overall clinical response (NB baseline HAM-D score did not 
differ between the two groups, responders and non-responders, Table 1, and equivalent 
results were obtained when the analysis was run without this covariate, Sup Table 4).  
The mask for the ACC as a priori region of interest was derived from the Harvard–Oxford 
Cortical anatomical atlas and used in small volume correction analysis SVC (clusters 
determined by Z>2.3 and a (corrected) cluster significance threshold of P=0.05). The mask 
included 1531 voxels. The results of group level the whole brain analyses were corrected 
using cluster-based thresholding with a height threshold of Z > 2·3 and a (whole-brain 
corrected) spatial extent threshold of P = 0.05. 
Additional analysis was performed with randomise, FSL’s non-parametric tool using 
Threshold-Free Cluster Enhancement (TFCE) thresholding approach, with baseline HAMD 
as a nuisance variable. This allowed for non-parametric permutation-based inference without 
a pre-defined arbitrary threshold, reducing the likelihood of false positive results Five 
thousand permutations were performed 
Predictive analysis 
In addition to the analysis described above, in which participant groups were defined based 
on future response to treatment, we were also interested in whether activity of the ACC could 
be used to predict response for individual patients. This was done using a leave-one-out 
approach in which training and testing data were kept completely separate. This analysis 
involved: firstly defining a cluster of voxels in which activity was greater for responders than 
non-responders to the sad-happy contrast within the ACC (NB the cluster was defined using 
Z>2.3 and p<0.05 with a structural ROI based on the Harvard-Oxford Cortical Atlas) using 
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just the training data (i.e. data from all but one participant). Secondly, extracting mean 
activity within this cluster for all participants, with the data from the training sample being 
used to generate a receiver operator characteristic (ROC) curve. Lastly, defining a cut-off 
from the ROC curve of the training data as the point furthest from the leading diagonal and 
classifying the held out participant as a responder or non-responder based on this cut-off. 
Note, this analysis was repeated for every participant and resulted in different clusters of 
voxels used in each classification as well as different cut-offs for the classification. This 
analysis provides an initial estimate of the ability of activity within the ACC to predict 
response at the level of the individual patient. 
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Results 
Clinical and demographic data 
After six weeks’ escitalopram treatment, 20 out of 32 patients (62%) were classified as 
responders.  There were no differences between responders and non-responders in terms of 
gender, age, baseline depression severity, baseline trait anxiety or duration of current episode 
(See Table 1).  
fMRI data 
ROI analysis. We performed SVC-corrected analysis of pgACC. In line with our hypothesis, 
we found an increased fMRI response to sad vs. happy faces in the group of patients who 
after 6 weeks responded to treatment, as compared to those who did not, both with and 
without controlling for baseline depression HAMD severity (family wise error (FWE)-
corrected P<0.05, SVC; 248 voxels, Z-value of the peak voxel 3.48, p=0.005). Exploring 
each emotion separately vs baseline showed that non-responders had numerically greater 
pgACC responses to both sad and happy faces, with the majority of the difference between 
the two groups apparently being due to altered responses to happy faces (Figure 1).  
While we used an ACC mask based on the commonly used Harvard–Oxford Cortical 
anatomical atlas, the part of the cluster identified can be described as located in the anterior 
midcingulate cortex (aMCC).  An additional analysis with a 600 voxel mask consisting only 
of volumes anterior to the genu of corpus callosum was run, and a similar response to 
reported above was observed in a cluster of 123 voxels, the part of the original cluster 
corresponding to strictly defined anterior cingulate cortex (results not reported).  
Whole-brain analysis. The exploratory analysis at the whole brain level using a parametric 
approach revealed a greater activation to sad vs happy faces in treatment responders as 
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compared to non-responders across a network of structures including ACC, paracingulate, 
right and left caudate, right thalamus and a small part of left thalamus, left putamen, and a 
small portion of fronto-occipital cortex, both when controlling for baseline depression 
HAMD severity, and not (P<·05, FWE corrected); see Figure 2. For details on functional 
clusters, see Table 2. The TFCE (Threshold-Free Cluster Enhancement) non-parametric 
method revealed a similar increased activation in response to sad vs happy faces in treatment 
responders vs non-responders across a network of structures, with the peak in the  ACC, and 
inclusing paracingulate gyrus, bilateral middle frontal gyrus, bilateral frontal orbital cortex, 
frontal pole, bilateral thalamus, and left insula. 
Prospective analysis allowed predicting classification into responders and non-responders 
with moderate accuracy of 71.875%. The centre of mass of the clusters is shown in Figure 2. 
A histogram of cut off scores and confusion matrix are shown in Figure 3 and 4, respectively.  
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Discussion 
Our study showed that pretreatment neural activation of pgACC in response to subliminal 
emotional information was predictive of short-term (6 weeks) therapeutic response to an 
SSRI escitalopram in patients with depression. A similar pattern was observed in a network 
of cortical and limbic areas associated with depression. Our findings support the body of 
evidence pointing to the ACC as currently the most reliable marker of response to various 
modes of treatment for depression and show its role in response to emotional information 
presented below the level of conscious awareness.  
Our findings are consistent with meta-analyses by Pizzagalli (2011) and Fu et al. (2013), and 
other more recent studies implicating the pgACC as the region in which baseline function is 
linked to future response to antidepressant treatment (eg. Klumpp 2017, Crane 2017, Cullen 
2016, Vai 2016, Dichter 2015, Victor 2013, Miller 2013, Kozel 2011, Roy 2010). Of recent 
investigations, the study by Victor et al. (2013) was of particular relevance to our 
investigation because it also employed an implicit emotional task based on presentation of 
masked sad and happy faces. Victor et al. (2013) found a decrease in the haemodynamic 
response in the pgACC to the contrast of masked sad vs happy faces after 8 weeks of 
treatment with another SSRI, sertraline, in 10 participants with depression. They also found a 
positive correlation between symptomatic improvement in depression ratings and baseline 
pgACC activation to masked sad vs happy faces, implicating pgACC in antidepressant 
response and its prediction. Studying a larger group of participants, and using a similar task 
based on masked presentation of emotions, we were also able to show differential baseline 
pre-treatment activity of the pgACC in treatment responders and non-responders.  
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The pgACC is a part of an extended medial prefrontal network, uniquely positioned with 
connections both to the amygdala and PFC (Drevets 2001, Mayberg 2003). It plays an 
important role in emotion appraisal and regulation, evaluation of the salience of emotional 
stimuli and emotion-related learning (Stevens et al. 2011), the processes that are dysregulated 
in depression and improve with successful treatment. Since the seminal publication by 
Mayberg et al. (1997), a wide range of research has consistently implicated pgACC as a brain 
region linked to treatment response. 
Increased activity in the pgACC was typically found to be predictive of better  treatment 
outcomes regardless of the  modality used to measure ACC activity (fMRI, PET, MEG and 
EEG), design  (ie. resting state or task-based) and form of treatment employed 
(pharmacotherapy, transcranial magnetic stimulation, CBT and sleep deprivation), as 
reviewed by Pizzagalli in 2011. Although only five out of 23 studies included in this review 
were fMRI studies, other fMRI studies have since been published, including a meta-analysis 
by Fu et al. (2013) of 20 functional neuroimaging papers (14 fMRI studies, 10 using various 
emotional processing tasks, and 4 using non-emotional tasks, and 6 PET studies in resting 
state conditions). Similar to Pizzagalli’s paper (2011), this meta-analysis showed a higher 
likelihood of improvement in response both to pharmacotherapy (14 included studies) or 
CBT (6 included papers) in patients with increased pre-treatment activation in the pgACC, as 
well as in subgenual and medial prefrontal cortices.  
Since the publication of these meta-analyses other studies, including ours (Godlewska et al., 
2016), have added to the relatively consistent body of evidence suggesting increased ACC 
activation during emotional processing and resting state as a putative marker of good clinical 
response to treatment. Although the results are not unequivocal (Fu et al. 2013) and are still 
some way off routine clinical application, currently the pgACC is considered to be one of the 
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most – if not the most – promising pre-treatment imaging biomarkers of antidepressant 
response, both because of its postulated role in the pathophysiology of depression and the 
consistency of reports on its role in treatment response prediction. 
In addition to the pgACC, our exploratory whole-brain analysis revealed a number of other 
regions showing a similar neural response to the employed task, ie. increased activity in 
response to sad vs happy facial expressions allowed differentiation between future treatment 
responders and non-responders. These regions included paracingulate cortex, thalamus, 
caudate, putamen, nucleus accumbens and orbitofrontal cortex (OFC) (Figure 2).  These 
structures are a part of networks involved in the processing of emotionally valenced 
information and reward, and their disruption has been hypothesized to contribute to low 
mood and anhedonia, core symptoms of depression (Graham et al. 2013, Fettes et al. 2017).  
The basal ganglia regions identified in this study: the caudate nucleus, the putamen and the 
nucleus accumbens, are involved in reward processing and form connections with the ACC 
and thalamus, with the ACC-basal ganglia-thalamus loop suggested to monitor unexpected 
events and to recruit adaptive mechanisms as required (Maia and Frank, 2011). Our results 
suggest that the pgACC is clearly a node in a distributed network of regions involved in 
processing of emotionally salient information. It is likely that differences in the function of 
this network, rather than solely in the pgACC function, are associated with antidepressant 
response.    
The period of time when response to antidepressants was assessed, six weeks into treatment, 
was chosen to be consistent with common clinical practice. Six weeks is around the time 
when clinicians often make decisions as to whether to continue treatment unchanged, adjust 
the dose or switch to a different medication, and is in line with current treatment guidelines 
(NICE Pathways, 2017). A reliable marker of this early response could potentially save a 
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patient from unnecessary weeks of delay in finding treatment they respond to. Treatment 
response was defined as baseline at least 50% decrease in HAMD scores as this definition, 
although somehow arbitrary, is a commonly used measure (Angst et al., 1993).  
To be clinically useful, a biomarker of treatment response needs to classify patients into 
responders and non-responders with reasonable  accuracy; so far no known biomarker has 
been consistently replicated in subsequent studies with accuracy high enough to be deemed 
useful in clinical practice (Fu and Costafreda 2013). Predictive analysis performed in this 
study allowed classification of participants into responders and non-responders with an 
accuracy of 71.9%, which differs from a probability of 0.5 with a p of 0.02. However, caution 
is required with this estimate of accuracy as leave-one-out (LOO) approaches to validation, as 
used in the current study, will tend to overestimate classifier accuracy when compared to 
validation in a fully held out sample (Hastie et al., 2009). This limitation is related to a 
number of statistical and methodological aspects of LOO procedures. First, clinically relevant 
classification requires between-dataset generalisation of classification performance 
(predictions need to be made on completely unseen data) which are not accounted for by 
LOO procedures which are based only on within dataset performance. Second, individual 
data points in LOO procedures will be used in all but one training sets, meaning that 
influential (e.g. outlying) data points can have exaggerated effects on classifier performance 
across training sets, which can skew estimates of classifier performance. As a result it will be 
essential to test whether pgACC activity is able to meaningfully predict treatment response in 
a fully held out sample of patients.  
A number of studies have used machine learning approaches to derive classifiers from fMRI 
data. These approaches tend to have many more predictors (i.e. voxels) than data points 
(patients) and are also difficult to interpret from a mechanistic perspective as they incorporate 
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complex interactions between predictors. In our study we used a very simple, univariate 
outcome from a pre-specified region which provides a mechanistically transparent predictor. 
Clearly however, it may be possible to improve on the predictive performance reported here 
by employing a multivariate approach to combine different features in the classifier. 
Additionally, there may well be alternative methods for deriving the predictive features from 
the fMRI data. In the current study we used mean signal change from clusters, defined in the 
training set. The clusters were defined on the basis of anatomical location (within the ACC) 
and statistical significance. It may be that using alternative methods for cluster/feature 
definition (e.g. changing the level of statistical significance for the cluster, or relaxing the 
anatomical specification) would increase the information contained in the cluster and 
improve classification performance.   
The ACC response seems to predict positive therapeutic outcome to many different kinds of 
treatment (Pizzagalli 2011, Fu et al. 2013). Therefore it does not currently point to selection 
of a particular antidepressant treatment modality or psychotherapy in preference to 
pharmacotherapy. Equally it does not suggest an alternative treatment regime for patients 
with low ACC responsivity who, at the moment, are predicted to do less well with various 
kinds of antidepressant therapies.  At the same time it may play an important role in 
identifying people with poor prognosis who can be given more intensive treatment from the 
start, leading to improving overall time to remission. It might also serve as a marker of 
efficacy when testing new drugs for antidepressant properties.  
Our study has some limitations. The main limitation is the small size of the group. The group 
itself was composed of carefully chosen drug free patients, yet increasing the number would 
increase the power and allow for more complex analyses combining different putative 
markers, an approach aiming at increasing accuracy of classification. The lack of a control 
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group may be considered as another limitation, however, the aim of the current study was to 
explore markers of treatment response prediction, for which a group of healthy volunteers or 
placebo treated patients is not strictly necessary. One limitation reflects a general question of 
feasibility of using imaging biomarkers in clinical settings, as scanning is not yet widely 
available and the procedure is still relatively costly. However, if the prediction using imaging 
biomarkers becomes sufficiently accurate, benefits including a decrease of depression burden 
on both individuals and society achieved through more efficient therapeutic processes could 
make it cost-effective.  
In summary, our study has shown that pre-treatment pgACC activity is predictive of response 
to antidepressant treatment after 6 weeks. It has also identified other brain regions where 
differential activity in response to an implicit emotional task had a similar predictive value. 
Our study adds to the growing body of evidence pointing at the pgACC as a reliable predictor 
of subsequent treatment response to a variety of therapeutic approaches to depression. 
Although the accuracy of classification in our study was moderate, it was higher than by 
chance and given that the pgACC pre-treatment function as response prediction marker has 
been the most consistently replicated neuroimaging finding, it makes it the most promising 
putative fMRI-based treatment response biomarker. To understand better the potential of 
pgACC imaging in this context, future studies are needed, on large groups and in patients at 
different stages of depression, employing machine learning approaches to combine pgACC 
effect with other neuroimaging and/or behavioural measures to increase classification 
accuracy. 
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Table 1. Demographic information for responders and non-responders to 6 weeks treatment 
with escitalopram. Presented as mean ± standard error (SE). 
 Responder s 
(n=20) 
Non-Responders 
(n=12) 
 
Gender 10F/10M 8F/4M p=0.358, 
χ2=0.847 
Age at the time of the 
scan (years) 
28.25 ± 2.64 28.75 ± 9.28 p=0.886, t=0.144 
Baseline depression 
severity (HAM-D) 
23.0 ± 1.1 23.67 ± 0.9 p=0.687, t=0.407 
Baseline depression 
severity (BDI-I) 
31.2 ± 1.5 33.1 ± 1.5 p=0.420, t=0.818 
Baseline trait anxiety 
(STAI-T) 
59.5 ± 1.9 63.2 ± 10.8 p=0.298, t=1.059 
Duration of current 4.5 ± 0.6 8.8 ± 2.6 p=0.06, t=1.992 
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episode (months) 
 
 
 
 
Table 2. Prediction of clinical response after 6 weeks of escitalopram treatment from baseline 
differences in pre-treatment neural response to sad compared with happy facial expressions. 
The table shows functional clusters identified by the exploratory analysis at the whole brain 
level. Please refer to Figure 1 for more details.    
Cluster content Peak voxel 
MNI Coordinates 
Cluster 
size, 
voxels 
Z-value P-value 
x y z 
Parametric approach (Gaussian Random Field Theory) 
Cluster A: 
L middle frontal gyrus, 
ACC, paracingulate 
gyrus, R caudate, R 
thalamus leaking into L 
thalamus 
-28 32 28 2173 3.66 0.000000238 
Downloaded from https://academic.oup.com/ijnp/advance-article-abstract/doi/10.1093/ijnp/pyy069/5074739
by Roehampton Institute user
on 22 August 2018
Ac
ce
pte
d M
an
us
cri
pt
 
28 
 
Cluster A: local maxima 22 12 16  3.59  
24 -28 26  3.59  
22 16 22  3.54  
30 26 24  3.53  
-6 30 20  3.48  
Cluster B: 
Frontal Orbital Cortex, L 
Putamen, L Caudate, L 
Accumbens 
-32 34 -4 544 3.68 0.0276 
Cluster B: local maxima -18 22 -4  3.37  
-28 40 -4  3.24  
-22 48 -8  3.04  
-24 12 -18  3.03  
-22 44 -8  3.00  
Cluster C: 
ACC, paracingulate 
gyrus 
26 36 0 523 3.7 0.0336 
Cluster C: local maxima 16 36 -4  3.37  
Downloaded from https://academic.oup.com/ijnp/advance-article-abstract/doi/10.1093/ijnp/pyy069/5074739
by Roehampton Institute user
on 22 August 2018
Ac
ce
pte
d M
an
us
cri
pt
 
29 
 
18 42 2  3.27  
34 42 -2  3.04  
20 26 10  3.03  
20 42 -8  2.89  
Non-parametric approach (Threshold-Free Cluster Enhancement) 
Cluster: 
ACC, paracingulate 
gyrus, bilateral Middle 
Frontal Gyrus, bilateral 
Frontal Orbital Cortex, 
Frontal pole, bilateral 
Thalamus, left Insula 
 
-4 30 16 6617 4.99 <0.05 
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Figure 1. Baseline differences in neural response (percent signal change) in the pgACC 
region of interest in response to sad vs happy facial expressions differentiated between 
responders and non-responders to 6 weeks treatment with escitalopram. The figure represents 
(a) results of SVC-corrected analysis in the anterior cingulate cortex using a parametric 
approach (Gaussian Random Field Theory); (b) extracted signal change in the identified 
cluster (mean and standard error); c) results of SVC-corrected analysis in the anterior 
cingulate cortex using a non-parametric approach (Threshold-Free Cluster Enhancement). 
Analysis was thresholded at Z=2.3 an  cluster-corrected with a FWE P<0.05. ACC, anterior 
cingulate cortex; FWE, family wise error; SVC, small volume correction. Baseline HAM-D 
scores were entered as a covariate.  
 
 
 
Figure 2. Baseline differences in neural response (percent signal change) at the whole brain 
level in response to sad vs happy facial expressions differentiated between responders and 
non-responders to 6 weeks treatment with escitalopram. The figure represents (a) results of 
the exploratory analysis at the whole brain level  using a parametric approach (Gaussian 
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Random Field Theory);  (b) extracted signal change in the identified clusters (mean and 
standard error); c) results of the exploratory analysis at the whole brain level using a non-
parametric approach (Threshold-Free Cluster Enhancement). Details of the clusters can be 
found in Table 2. Analysis was thresholded at Z=2.3 and cluster-corrected with a FWE 
P<0.05. ACC, anterior cingulate cortex; FOC fronto-orbital cortex; FWE, family wise error. 
Baseline HAM-D scores were entered as a covariate.  
Figure 3. Confusion plot. Green squares represent correctly classified cases: TP – true 
positives, TN – true negatives, the number of correct classifications by the trained network, 
percentage of all cases they represent. Red squares represent incorrectly classified cases: FP – 
false positives, FN – false negatives, the number of correct classifications by the trained 
network, percentage of all cases they represent. The blue square represents the percentage of 
correct and incorrect classifications.  
The first row represents predicted non-responders, of whom 61.5% were classified correctly, 
and 38.5% incorrectly. The second row represents predicted responders, of whom 78.9% 
were classified correctly, and 21.1% incorrectly. Out of 12 non-responders, 66.7% were 
correctly predicted as non-responders and 33.3% were predicted as responders. Out of 20 
responders, 75% were correctly classified as responders and 25% were classified as non-
responders. Overall, 71.9% of the predictions were correct and 28.1% cases were classified 
incorrectly. 
 
Figure 4. Histogram of the cut off scores used in the classifier.  
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Figure 1. 
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Figure 2. 
 
Downloaded from https://academic.oup.com/ijnp/advance-article-abstract/doi/10.1093/ijnp/pyy069/5074739
by Roehampton Institute user
on 22 August 2018
Ac
ce
pte
d M
an
us
cri
pt
 
34 
 
Figure 3. 
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Figure 4. 
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